Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Lathia, Justin D  [Clear All Filters]
2013
Lathia JD. Cancer stem cells: moving past the controversy. CNS Oncol. 2013;2(6):465-467.
Hale JS, Sinyuk M, Rich JN, Lathia JD. Decoding the cancer stem cell hypothesis in glioblastoma. CNS Oncol. 2013;2(4).
Liu WMichael, Huang P, Kar N, Burgett M, Muller-Greven G, Nowacki AS, Distelhorst CW, Lathia JD, Rich JN, Kappes JC, et al. Lyn Facilitates Glioblastoma Cell Survival under Conditions of Nutrient Deprivation by Promoting Autophagy. PLoS One. 2013;8(8):e70804.
2014
Hale JS, Otvos B, Sinyuk M, Alvarado AG, Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML, et al. Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells. 2014.
2015
Sinyuk M, Alvarado AG, Nesmiyanov P, Shaw J, Mulkearns-Hubert EE, Eurich JT, Hale JS, Bogdanova A, Hitomi M, Maciejewski J, et al. Cx25 contributes to leukemia cell communication and chemosensitivity. Oncotarget. 2015.
2016
Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, Rayman P, Flavahan WA, Hale JS, Stoltz K, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells. 2016.
Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, Hitomi M, Nagaraj ABelur, DiFeo A, Lathia JD, et al. Cisplatin induces stemness in ovarian cancer. Oncotarget. 2016.
Dermawan JKam Tai, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, et al. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res. 2016.
Alvarado AG, Lathia JD. Taking a Toll on Self-Renewal: TLR-Mediated Innate Immune Signaling in Stem Cells. Trends Neurosci. 2016.
2018
Ostrom QT, Coleman W, Huang W, Rubin JB, Lathia JD, Berens ME, Speyer G, Liao P, Wrensch MR, Eckel-Passow JE, et al. Sex-specific gene and pathway modeling of inherited glioma risk. Neuro Oncol. 2018.
2019
Mulkearns-Hubert EE, Torre-Healy LA, Silver DJ, Eurich JT, Bayik D, Serbinowski E, Hitomi M, Zhou J, Przychodzen B, Zhang R, et al. Development of a Cx46 Targeting Strategy for Cancer Stem Cells. Cell Rep. 2019;27(4):1062-1072.e5.
Esakov EL, Hale J, Richards EG, Torre-Healy L, Gullapalli K, Trivedi, iv D, Chumakova A, Wessely O, Jensen J, Lathia JD, et al. Therapeutic strategies to induce ERα in luminal breast cancer to enhance tamoxifen efficacy. Endocr Relat Cancer. 2019.
2020
Turaga SM, Silver DJ, Bayik D, Paouri E, Peng S, Lauko A, Alban TJ, Borjini N, Stanko S, Naik U, et al. JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro Oncol. 2020.
2021
Silver DJ, Roversi GA, Bithi N, Wang SZ, Troike KM, Neumann CKa, Ahuja GK, Reizes O, J Brown M, Hine C, et al. Severe consequences of a high-lipid diet include hydrogen sulfide dysfunction and enhanced aggression in glioblastoma. J Clin Invest. 2021.
2023
Lee J, Kay KE, Vogelbaum MA, Lathia JD. Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM. Cancer Immunol Res. 2023:OF1-OF2.
Sloan AR, Thapliyal M, Lathia JD. New T-cell therapies for brain metastasis, CD133 in the driver's seat. Clin Cancer Res. 2023.
Alban TJ, Grabowski MM, Otvos B, Bayik D, Wang W, Zalavadia AH, Makarav V, Troike KM, McGraw M, Rabljenovic A, et al. The SNP rs755622 is associated with immune activation in glioblastoma. JCI Insight. 2023.
Hubert CG, Stauffer SR, Lathia JD. A TOX-ic axis of epigenetic stem cell maintenance and chemoresistance in colon cancer. PLoS Biol. 2023;21(9):e3002295.
Mitchell K, Sprowls SA, Arora S, Shakya S, Silver DJ, Goins CM, Wallace L, Roversi G, Schafer R, Kay K, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev. 2023.
2024
Álvarez-Vázquez A, San-Segundo L, Cerveró-García P, Flores-Hernández R, Ollauri-Ibáñez C, Segura-Collar B, Hubert CG, Morrison G, Pollard SM, Lathia JD, et al. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models. Neuro Oncol. 2024.